24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Race and Gender May Tip the Scales on Traditional Stroke Risk FactorsMeasles Complications Can Affect Every Organ: StudyBabies' Exposure to Household Cleaning Products Tied to Later Asthma RiskCoronavirus: Are U.S. Hospitals Prepared?14 Americans From Cruise Ship Hit By Coronavirus Test Positive for InfectionHot Chocolate Could Help Ease Painful Clogged Leg VesselsAntiviral Drug, Plasma Transfusions Show Promise in Treating CoronavirusHow to Dispel Your Child's Fears About the New CoronavirusCholesterol Drugs Might Help Curb 'High-Risk' Prostate CancersCoronavirus Spreads Most Easily When Patients Are Sickest: CDCWill Brushing and Flossing Protect You Against Stroke?Young Black Adults More Prone to Stroke, but Don't Know ItAHA News: Stroke Rates Down for Mexican Americans, Up for White AdultsCoronavirus Cases, Deaths Rise Sharply, While 2 New Cases Reported in U.S.Scientists Spot Antibody That Might Help Diagnose, Treat Autoimmune DisordersCoronavirus in America: Keep Your Panic in CheckCoronavirus Spread Slows, But Death Toll Jumps to 1,113Growing Up in U.S. 'Stroke Belt' Bad for the Brain Later in LifeShingles Vaccine Bonus: Reduced Risk of Stroke?Air Pollution Made in One State Can Cause Deaths in OthersWere You Born in an H1N1 Flu Year or an H3N2? It MattersStricter Clean Air Laws Could Save Thousands of Lives a Year: StudyCoronavirus Fears Have U.S. Pharmacies Running Out of Face MasksCoronavirus Death Toll Tops 1,000, While 13th U.S. Case ConfirmedMeds May Not Prevent Migraines in KidsHigh Testosterone Levels Have Different Health Impact for Men and WomenCoronavirus Cases Top 40,000, While Deaths Hit 908With Macular Degeneration, 1 Missed Visit to Eye Doc Can Mean Vision LossHundreds Suspected, 12 Confirmed: How CDC Identified U.S. Coronavirus CasesFor Patients on Blood Thinners, GI Bleeding May Signal Colon Cancer: StudyStudy Finds 'No Clear Rationale' for 45% of Antibiotic PrescriptionsThere's a Virus Spreading in U.S. That's Killed 10,000: The FluSome U.S. Workers Are Bringing Toxins Home to Their KidsAHA News: Expert Heart Advice for Rare Genetic Muscle Disorder9/11 Study Shows PTSD Tied to Earlier DeathWorkers With Cluster Headaches Take Twice as Many Sick DaysMore Americans to Be Evacuated From China; 12th Coronavirus Case ReportedYoung-Onset Parkinson's May Start in the Womb, New Research SuggestsHealthy Habits Can Slide After Starting Heart MedicationsWide Variations Found in 'Normal' Resting Heart RateLab Discovery Offers Promise for Treating Multiple SclerosisIs Vaping a Scourge on Your Skin?Many Can Suffer Facial Paralysis -- and Its Emotional TollAHA News: Persistent Asthma Linked to Increased Risk for Heart Rhythm DisorderAs Health Experts Fear Possible Pandemic, 2nd Death Reported Outside ChinaBedside 'Sitters' May Not Prevent Hospital FallsFirst Drug Approved for Treatment of Peanut Allergy in ChildrenAHA News: Millions Are Learning to Live With Heart FailureDoes Race Play a Part in ICU Outcomes?Meat Still Isn't Healthy, Study Confirms
Questions and AnswersLinks
Related Topics

Diabetes

Hormone Therapy for Prostate Cancer Might Harm the Heart: Study

HealthDay News
by By Amy Norton
HealthDay Reporter
Updated: Aug 13th 2019

new article illustration

TUESDAY, Aug. 13, 2019 (HealthDay News) -- When men have both advanced prostate cancer and heart disease, treatment may pose a dilemma: Newer hormonal therapies that can slow the cancer down might also be risky for their hearts, a new study finds.

Once prostate cancer spreads beyond the gland, one of the mainstays of treatment is hormone therapy. The aim is to prevent androgens ("male" hormones such as testosterone) from feeding the cancer's growth.

Doctors have known that hormone therapy may increase a man's risk of developing heart disease. Its potential side effects include spikes in blood sugar, blood cholesterol and body fat -- all of which contribute to heart problems.

But newer types of hormone therapy have become available in the past seven to eight years. And much less is known about their heart-related risks, said lead researcher Grace Lu-Yao, professor of medical oncology at Thomas Jefferson University in Philadelphia.

So her team focused on older patients who'd received either abiraterone (Zytiga) or enzalutamide (Xtandi) -- two newer pills that suppress androgens.

Overall, the study found, men with cardiovascular disease were at somewhat higher risk of dying within six months of starting treatment, versus other patients.

The risk was most clear among men with three or more cardiovascular conditions: They were roughly 50% more likely to die, versus men with healthy hearts.

Cardiovascular disease included atherosclerosis (clogged heart arteries), heart failure, atrial fibrillation (a heart rhythm disorder), or a history of heart attack or stroke.

The reasons for the findings are not completely clear, according to Lu-Yao.

But the drugs can raise blood pressure, contribute to fluid buildup, and affect blood levels of sodium or potassium.

Those effects might help explain the higher death risk, Lu-Yao said. Another possibility, she added, is that the drugs might interact with certain heart medications.

The findings do not mean that men with heart conditions should refuse hormonal therapies, according to Lu-Yao.

But, she said, they should discuss the benefits and risks with their doctor before making a treatment decision.

"And once they start treatment, they would need close monitoring," Lu-Yao said.

The study was partly funded by the U.S. National Institutes of Health. It was published Aug. 13 in the journal European Urology.

The initial trials that won approval for abiraterone and enzalutamide excluded patients with "significant" cardiovascular conditions.

In the real world, though, many men with prostate cancer have heart disease -- and they receive the hormonal therapies, said Dr. Salim Hayek, a cardiologist who focuses on the heart health of cancer patients.

Hayek, who was not involved in the study, is a member of the American College of Cardiology's cardio-oncology section leadership council.

He stressed that this study should not scare patients away from hormone therapies. "There's no data saying that the risks outweigh the benefits of these drugs," Hayek said.

But he agreed that men with heart disease should be monitored while taking the medications -- and they should keep seeing their cardiologist.

"After a cancer diagnosis, the cancer often becomes the focus," Hayek said. "But cardiovascular health should not be neglected."

The findings are based on nearly 3,900 elderly U.S. men treated for advanced prostate cancer with abiraterone or enzalutamide. Half were age 75 or older, and two-thirds had a preexisting cardiovascular condition.

In general, those men had a higher death rate within six months. For example, more than 2,200 men received abiraterone and no prior chemotherapy: The death rates among those with atrial fibrillation, heart failure or a past heart attack hovered between 23% and 25%, compared with 14% among men free of cardiovascular problems.

When the researchers weighed other factors -- such as age and other health issues -- men with one or two cardiovascular conditions were 16% more likely to die than men without those diseases. The risk among men with three or more conditions was 43% to 56% higher.

But could it be the heart issues, rather than the drugs? Lu-Yao doubted that, partly based on another finding: In the six months after starting abiraterone, hospitalizations rose among men with heart disease, versus the six months before. (The same was not seen with enzalutamide, however.)

More studies, Lu-Yao said, are needed to understand why -- including whether the hormone therapy interacts with other medications and increases the risk of side effects from them.

More information

The American Cancer Society has more on hormone therapy for prostate cancer.